Wednesday, August 19, 2026
Approved
approved Note: Approved 2026-08-19 as PASATRU (ORIG BLA761508). Auto-resolved from data/drugs.json by scripts/pdufa/resolve-outcomes.cjs on 2026-08-28; 0d from the PDUFA date.
Drug Information
- Drug Name
- Garetosmab (CT.gov)
- Application Type
- BLA
- FDA Designations
- Priority ReviewOrphan DrugFast Track
- Indication
- Fibrodysplasia ossificans progressiva (FOP) in adults
- Approved As
- Garetosmab
Filing Details
- Stock Ticker
- REGN
- SEC CIK
- 0000872589
- Source
- Company IR →
What is a PDUFA Date?
A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.
- Standard Review: 10 months from filing acceptance
- Priority Review: 6 months from filing acceptance
- Possible Outcomes: Approval, Complete Response Letter (CRL), or extension
Explore Regeneron Pharmaceuticals, Inc.
View Regeneron Pharmaceuticals, Inc.'s full pipeline, approved drugs, and clinical trials.
Data sourced from SEC EDGAR filings. Last updated: 2026-04-20. Report an issue